Zynyz
What Zynyz is used for
Squamous cell carcinoma of the anal canal (SCAC) Zynyz is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). Merkel cell carcinoma (MCC) Zynyz is indicated as monotherapy for the first line treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) not amenable to curative surgery or radiation therapy.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Zynyz
- Active substance
- retifanlimab
- Disease area
- Carcinoma, Merkel Cell
- Medicine group
- Antineoplastic agents
- ATC code
- L01FF10
- Marketing authorisation holder
- Incyte Biosciences Distribution B.V.
- Authorised in the EU since
- 2024
Official information
In the USA
Same active substance: Zynyz
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Zynyz used for?
Squamous cell carcinoma of the anal canal (SCAC) Zynyz is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). Merkel cell carcinoma (MCC) Zynyz is indicated as monotherapy for the first line treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) not amenable to curative surgery or radiation therapy.
What is the active substance in Zynyz?
Zynyz contains retifanlimab.
Who makes Zynyz?
The EU marketing authorisation holder is Incyte Biosciences Distribution B.V..
Is Zynyz an orphan medicine?
Yes. Zynyz is designated an orphan medicine in the EU, for a rare disease (Carcinoma, Merkel Cell).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU